Granted Patent
B2
US 12,729,235 · App. 17/341,212 · Granted Sep 8, 2026
Caninized anti-TGFβ antibodies
Inventors:
Lisa Marie Bergeron (Boulder, CO); Gary F. Bammert (Kalamazoo, MI); Henry Luis Campos (Kalamazoo, MI); Sandra Ann Marie Lightle (Kalamazoo, MI); Catherine J. Strietzel (Kalamazoo, MI)
Assignee:
Zoetis Services LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure encompasses anti-TGFβ antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of TGFβ-related disorders, particularly in for the management of fibrosis related disorders in canines and felines.
Claims (18)
1 . A caninized antigen binding protein that specifically binds Transforming Growth Factor Beta-1 (TGFβ1) and wherein said antigen binding protein further specifically binds to canine Transforming Growth Factor Beta-3 (TGFβ3), wherein said protein comprises:
a. a heavy chain variable region (VH) comprising:
i. a Complimentary Determining Region 1 (CDR1) comprising an amino acid sequence comprising SEQ ID NO. 5;
ii. a Complimentary Determining Region 2 (CDR2) comprising an amino acid sequence comprising SEQ ID NO. 6;
iii. a Complimentary Determining Region 3 (CDR3) comprising an amino acid sequence comprising SEQ ID NO: 7; and
b. a light chain variable region (VL) comprising:
i. a Complimentary Determining Region 1 (CDR1) comprising an amino acid sequence comprising SEQ ID NO. 8;
ii. a Complimentary Determining Region 2 (CDR2) comprising an amino acid sequence comprising SEQ ID NO. 9; and
iii. a Complimentary Determining Region 3 (CDR3) comprising an amino acid sequence comprising SEQ ID NO: 10.
2 . The antigen binding protein of claim 1 , wherein the antigen binding protein comprises:
a. a heavy chain variable region (VH) comprising amino acid sequences selected from the group consisting of: SEQ ID NO:12; SEQ ID NO:14; SEQ ID NO:16; and
b. a light chain variable region (VL) comprising amino acid sequence SEQ ID NO:24.
3 . The antigen binding protein of claim 2 , wherein said antigen binding protein comprises a heavy chain variable region (VH) comprising amino acid sequence SEQ ID NO. 12; and a light chain variable region (VL) SEQ ID NO. 24.
4 . The antigen binding protein of claim 3 , wherein said antigen binding protein further comprises a constant region of the heavy chain comprising SEQ ID NO.127 and the constant region of the light chain comprising SEQ ID NO. 129.
5 . The antigen binding protein of claim 1 , wherein said protein is selected from the group consisting of: a monoclonal antigen binding protein; a tetrameric antigen binding protein, a tetravalent antigen binding protein, a multispecific antigen binding protein, and a fusion protein.
6 . The antigen binding protein of claim 5 , wherein said antigen binding protein is a monoclonal antigen binding protein.
7 . A pharmaceutical composition comprising the antigen binding protein of claim 1 and a pharmaceutically acceptable carrier.
8 . A method of inhibiting TGFβ in a subject in need thereof by administering to said subject the pharmaceutical composition of claim 7 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 15, 2021
From: BERGERON, LISA MARIE; BAMMERT, GARY F.; CAMPOS, HENRY LUIS; LIGHTLE, SANDRA ANN MARIE; STRIETZEL, CATHERINE J.
To: ZOETIS SERVICES LLC
Reel/Frame 056552/0800 →
Continuity (2)
Provisional Application
63036092
· Jun 8, 2020
References Cited (117)
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5350576A
· Payne et al.
· 1994
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 6194167B1
· Browse et al.
· 2001
[cited by applicant]
US 6492497B1
· Thompson et al.
· 2002
[cited by applicant]
US 6774107B1
· Strittmatter et al.
· 2004
[cited by applicant]
US 6790639B2
· Brown et al.
· 2004
[cited by applicant]
US 7261890B2
· Krah, III et al.
· 2007
[cited by applicant]
US 7723486B2
· Ledbetter et al.
· 2010
[cited by applicant]
US 9505829B2
· Lacy et al.
· 2016
[cited by applicant]
US 9617334B2
· Bergeron et al.
· 2017
[cited by applicant]
US 20030031671A1
· Welt et al.
· 2003
[cited by applicant]
EP 0388151A1
· 1990
[cited by applicant]
WO 2005092925A2
· 2005
[cited by applicant]
WO WO2013134365A1
· 2013
[cited by applicant]
WO WO2014164709A2
· 2014
[cited by applicant]
WO WO2016141245A1
· 2016
[cited by applicant]
WO WO2018208670A1
· 2018
[cited by applicant]
WO 2018237157A1
· 2018
[cited by applicant]
WO 2019108900A1
· 2019
[cited by applicant]
WO WO2020095113A1
· 2020
[cited by applicant]
WO 2021252455A1
· 2021
[cited by applicant]
WO 2023049917A1
· 2023
[cited by applicant]
Simpson et al. (The Laryngoscope 118: 543-551, 2008).
[cited by examiner]
Silva, R. F. et al., 2012, “Comparison of the effect of calcium gluconate and batroxobin on the release of transforming growth factor beta 1 in canine platelet concentrates”, BMC Veterinary Research, Biomed Central, vol…
[cited by applicant]
Uniprot Database, Oct. 10, 2018, “TGFBR2—TGF-beta receptor type-2—Felis catus (Cat)—TGFBR2 Gene & protein”, Accession No. M3W233.
[cited by applicant]
Jin, G. et al., 2007, “TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population”, Journal of Cancer Research and Clinical Oncology, vol. 1…
[cited by applicant]
Maeda, M. et al., 2017, “Effects of Gelatin Hydrogel Containing Anti-Transforming Growth Factor-β Antibody in a Canine Filtration Surgery Model”, International Journal of Molecular Sciences, vol. 18, p. 985.
[cited by applicant]
Simpson, C. B. et al., 2008, “Anti-transforming growth factor beta as a treatment for laryngotracheal stenosis in a canine model”, The Laryngoscope, Wiley-Blackwell, vol. 118, No. 3, Mar. 1.
[cited by applicant]
Davis, R. J., et al., 2020, “Inflammatory pathways in the pathogenesis of iatrogenic laryngotracheal stenosis: what do we know?”, Translational Cancer Research, vol. 9, pp. 2108-2116.
[cited by applicant]
Buhren, J. et al., 2009, “Optical Effects of Anti-TGFβ Treatment after Photorefractive Keratectomy in a Cat Model”, Investigative Ophthalmology & Visual Science, vol. 50, pp. 634-643.
[cited by applicant]
Dasch, J. R. et al., 1989, “Monoclonal Antibodies Recognizing Transforming Growth Factor-β, Bioactivity Neutralization and Transforming Growth Factor β2 Affinity Purification”, The Journal of Immunology, vol. 142, pp. 1…
[cited by applicant]
Komai, T. et al., 2018, “Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals”, Frontiers in Immunology, vo. 9, article 1364.
[cited by applicant]
Tabe, Y. et al, 2013, “TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment”, PLoS One, vol. 8, e62785.
[cited by applicant]
Bedinger, D. et al., 2016, “Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ Isoforms”, MABS, vol. 8, pp. 389-404.
[cited by applicant]
Rice, L. M. et al., 2015, “Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients”, The Journal of Clinical Investigation, vo. 125, pp. 2795-2807.
[cited by applicant]
Liang, X. et al., 2016, “Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria”, PLoS One, pp. 1-17.
[cited by applicant]
Lord, D. M. et al., 2018, “Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody”, MABS, vol. 10, pp. 444-452.
[cited by applicant]
Denton, C. P. et al, 2007, “Recombinant Human Anti-Transforming Growth Factor β1 Antibody Therapy in Systemic Sclerosis; A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192”, Arthritis & Rheumatism…
[cited by applicant]
Voelker, J. et al., 2017, “Anti-TGF-β1 Antibody Therapy in Patients with diabetic Nephropathy”, Journal of American Society of Nephrology, vol. 28, pp. 953-962.
[cited by applicant]
Kanasaki, K. et al., 2013, “Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis”, Frontiers in Endocrinology, vol. 4, article 7.
[cited by applicant]
Zoetis, “Advances in Veterinary Medicine: Therapeutic Monoclonal Antibodies for Companion Animals” Internet: URL:https://www.zoetisus.com/conditions/dogs/itchycle/downloads/resorces/publications/zoetisn marfnl.pdf [retr…
[cited by applicant]
Lawson, J. S. et al., 2018, “The cat as a naturally occurring model of renal interstitial fibrosis: Characterisation of primary feline proximal tubular epithelial cells and comparative pro-fibrotic effects of TGF-β1”, P…
[cited by applicant]
Gu, Y. et al., 2020, “Diverse Role of TGF-β in Kidney Disease,” Frontiers in Cell and Developmental Biology, vol. 8, article 123.
[cited by applicant]
Perez, J. M. et al., 2018, “Critical Approach to the Alternative Treatment of Chronic Kidney Disease in Dogs and Cats”, Slovenian Veterinary Research, vol. 55, pp. 59-71.
[cited by applicant]
Kabat et al.,1991, Sequences of Proteins of Immunological Interest, 5
[cited by applicant]
Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5
[cited by applicant]
Kabat et al., 1991, Sequences of Proteins of Immunological Interest, 5
[cited by applicant]
Chothia, C, et al., 1987, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, Journal of Molecular Biology, vol. 196, pp. 901-917.
[cited by applicant]
Da{tilde over (e)}ron, M., 1997, “Fc Receptor Biology”, Annual Review of Immunology, vol. 15, pp. 203-234.
[cited by applicant]
Armour, K. L. et al., 1999, “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities”, European Journal of Immunology, vol. 29, pp. 2613-2624.
[cited by applicant]
Clynes, R. A. et al., 2000, “Inhibitory FC receptors modulate in vivo cytoxicity against tumor targets”, Nature Medicine, vol. 6, pp. 443-446.
[cited by applicant]
Schifferli, J. A. et al., 1986, “The Role of Complement and its Receptor in the Elimination of Immune Complexes”, The New England Journal of Medicine, vol. 315, pp. 488-495.
[cited by applicant]
Garred, P. et al., 1989, “The IgG Subclass Pattern of Complement Activation Depends on Epitope density and Antibody and Complement Concentration”, Scandinavian Journal of Immunology, vol. 30, pp. 379-382.
[cited by applicant]
Moore, G. L. et al., 2010, “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions”, mABs, vol. 2, pp. 181-189.
[cited by applicant]
Ghetie, V. et al., 1996, “Abnormally short serum half-lives of IgG in B2 microglobulin-deficient mice”, European Journal of Immunology, vol. 26, pp. 690-696.
[cited by applicant]
Israel, E. J. et al., 1996, “Increased clearance of IgG in mice that lack β
[cited by applicant]
Praetor, A. et al., 2002, “Membrane-anchored Human FcRn can Oligomerize in the Absence of IgG”, Journal of Molecular Biology, vol. 321, pp. 277-284.
[cited by applicant]
Jefferis, R., 2007, Antibody therapeutics: isotype and glycoform selection, Expert Opinion on Biological Therapy, vol. 7, pp. 1401-1413.
[cited by applicant]
Mazza, G. et al., 1993, “The separation and identification by monoclonal antibodies of dog IgG fractions”, Journal of Immunological Methods, vol. 161, pp. 193-203.
[cited by applicant]
Bergeron, L. M. et al., 2014, “Comparative functional characterization of canine IgG subclasses”, Veterinary Immunology and Immunopathology, vol. 157, pp. 31-41.
[cited by applicant]
Strietzel, C. J. et al., 2014, “In Vitro functional characterization of feline IgGs,” Veterinary Immunology and Immunopathology, vol. 158, pp. 214-223.
[cited by applicant]
Kanai, T. H. et al., 2000, “Identification of two allelic IgG1 CH coding regions (Cy1) of cat”, Veterinary Immunology and Immunopathology, vol. 73, pp. 53-62.
[cited by applicant]
Ravetch, J. V. et al., 1991, “Fc receptors”, Annual Review Immunology, vol. 9, pp. 457-492.
[cited by applicant]
Capel, P. J. A. et al., 1994, “Heterogeneity of Human IgG Fc Receptors”, Immunomethods, vol. 4, pp. 25-34.
[cited by applicant]
De Haas et al., 1995, “Fc gamma receptors of phagocytes”, Journal of Laboratory and Clinical Medicine, vol. 126, pp. 330-341.
[cited by applicant]
Guyer, R. L. et al., 1976, “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors”, Journal of Immunology, vol. 117, pp. 587-593.
[cited by applicant]
Kim, J. et al., 1994, Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor, Journal of Immunology, vol. 24, pp. 2429-2434.
[cited by applicant]
Clynes, R. et al., 1998, “Fc receptors are required in passive and active immunity to melanoma”, PNAS (USA), vol. 95, pp. 652-656.
[cited by applicant]
Gazzano-Santoro, H. et al., 1997, “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” Journal of Immunological Methods, vol. 202, p. 163-171.
[cited by applicant]
Kohler, G. et al., 1975, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, vol. 256, pp. 495-497.
[cited by applicant]
Clackson, T. et al., 1991, “Making antibody fragments using phage display libraries”, Nature, vol. 352, pp. 624-628.
[cited by applicant]
Marks, J. D. et al., 1991, “By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage”, Journal of Molecular Biology, vol. 222, pp. 581-597.
[cited by applicant]
Taylor, L. D. et al., 1992, “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins”, Nucleic Acids Research, vol. 20, pp. 6287-6295.
[cited by applicant]
Sivalingam, G. N. et al., 2012, “An analysis of B-cell epitope discontinuity”, Molecular Immunology, vol. 51, pp. 304-309.
[cited by applicant]
McCumber, L. J. et al., 1979, “The Complete Amino-Acid Sequence of a Canine MU Chain”, Molecular Immunology, vol. 16, pp. 565-570.
[cited by applicant]
Tang, L. et al., 2001, “Cloning and characterization of cDNAs encoding four different canine immunoglobulin y chains”, Veterinary Immunology and Immunopathology, vol. 80, pp. 259-270.
[cited by applicant]
Potter, K. N. et al., 1993, “Antibody Production in the Baculovirus Expression System”, International Reviews of Immunology, vol. 10, pp. 103-112.
[cited by applicant]
Houdebine, L., 2002, Antibody manufacture in transgenic animals and comparisons with other systems, Current Opinion in Biotechnology, vol. 13, pp. 625-629.
[cited by applicant]
Schillberg, S. et al., 2003 “Molecular farming of recombinant antibodies in plants”, Cellular and Molecular Life Sciences, vol. 60, pp. 433-445.
[cited by applicant]
Lathe, R., 1985, “Synthetic oligonucleotide probes deduced from amino acid sequence data: theoretical and practical considerations”, Journal of Molecular Biology, vol. 183, pp. 1-12.
[cited by applicant]
PCT International Search Report and Written Opinion, International Application No. PCT/US2021/036347, International Filing Date Jun. 8, 2021, Date of Mailing Nov. 23, 2021, Bumb, P.—authorized officer.
[cited by applicant]
Akhurst R.J., et al., “Targeting the TGFBeta Signalling Pathway in Disease”, Nature Reviews Drug Discovery, 2012, vol. 11, No. 10, pp. 790-811.
[cited by applicant]
Bedouelle H., et al., “Diversity and Junction Residues as Hotspots of Binding Energy in a Antibody Neutralizing the dengue Virus,” FEBS Journal, Jan. 2006, vol. 273, pp. 34-46.
[cited by applicant]
Brown M., et al., “Tolerance of Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR 2: A Means of Minimizing B Cell Wastage From Somatic Hypermutation?,” Journal of Immunology, May 1996, vol. 156, No. 9…
[cited by applicant]
Chen C., et al., “Enhancement and Destruction of Antibody Function by Somatic Mutation: Unequal Occurrence Is Controlled by V Gene Combinatorial Associations”, The EMBO Journal, vol. 14, No. 12, Jun. 15, 1995, pp. 2784-…
[cited by applicant]
Colman P. M., et al., “Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions”, Research in Immunology, vol. 145, No. 1, Jan. 1994, pp. 33-36.
[cited by applicant]
“Integrated Into UniProtKB/Swiss-Prot”, Accession No. P04202, Entry Version 216, Apr. 20, 2020, 9 Pages, Retrieved from https://rest.uniprot.org/unisave/P04202?format=txt&versions=216, Search Date May 9, 2025.
[cited by applicant]
“Integrated Into UniProtKB/Swiss-Prot” Accession No. P17125, Entry Version 165, Feb. 26, 2020, 5 Pages, Retrieved from https://rest.uniprot.org/unisave/P17125?format=txt&versions=165, Search Date May 9, 2025.
[cited by applicant]
“Integrated Into UniProtKB/Swiss-Prot”, Accession No. P27090, Entry Version 175, Apr. 22, 2020, 7 Pages, Retrieved from https://rest.uniprot.org/unisave/P27090?format=txt&versions=175, Search Date May 9, 2025.
[cited by applicant]
“Integrated into UniProtKB/TrEMBL”, Accession No. F1PKH0, Apr. 22, 2020, Entry Version 60, 4 Pages, Retrieved from https://rest.uniprot.org/unisave/F1PKH0?format=txt&versions=60, Last Accessed on May 9, 2025.
[cited by applicant]
“Integrated Into UniProtKB/TrEMBL”, Accession No. Q2PPL2, Entry Version 61, Feb. 26, 2020, 2 Pages, Retrieved from https://rest.uniprot.org/unisave/Q2PPL2?format=txt&versions=61, Last Searched on May 9, 2025.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/077053, dated Apr. 11, 2024, 8 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/077053, dated Feb. 7, 2023, 11 Pages.
[cited by applicant]
Janeway C.A., et al., “The Recognition of Antigen,” Immuno Biology, The Immune System in Health and Disease, Immunology, 3rd edition, Garland Publications, Inc., 1997, pp. 3:1-3:11 (14 Pages).
[cited by applicant]
Johnston S.A., et al., “Mitochondrial Transformation in Yeast by Bombardment with Microprojectiles”, Science, 1988, vol. 240, pp. 1538-1541.
[cited by applicant]
Krafft E., et al., “Transforming Growth Factor Beta 1 Activation, Storage, and Signaling Pathways in Idiopathic Pulmonary Fibrosis in Dogs”, Journal of Veterinary Internal Medicine, 2014, vol. 28, No. 6, pp. 1666-1675, …
[cited by applicant]
Liang W-C., et al., “Dramatic Activation of an Antibody by a Single Amino Acid Change in Framework”, Scientific Reports, 2021, vol. 11, No. 22365, 9 Pages, See Abstract.
[cited by applicant]
Macarenhas J., et al., “Anti-Transforming Growth Factor-(beta) Therapy in Patients with Myelofibrosis,” Leukemia & Lymphoma, Feb. 2014, vol. 55, No. 2, pp. 450-452 (4 Pages).
[cited by applicant]
NCI: “Anti-TGF-beta Monoclonal Antibody GC1008,” National Cancer Institute, 2024, 1 Page, [Retrieved on Dec. 13, 2024].
[cited by applicant]
Pascal B.D., et al., “HDX Workbench: Software for the Analysis of H/D Exchange MS Data”, Journal of the American Society for Mass Spectrometry, 2012, vol. 23, No. 9, pp. 1512-1521.
[cited by applicant]
Rudikoff S., et al., “Single Amino Acid Substitution Altering Antigen-binding Specificity,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 1982, vol. 79, pp. 1979-1983(5 Pages).
[cited by applicant]
Schenderov K., et al., “Immune Dysregulation as a driver of Idiopathic Pulmonary Fibrosis,” Journal of Clinical Investigation, Jan. 19, 2021, vol. 131, No. 2, Article No. e143226, 9 Pages.
[cited by applicant]
Shah P.V., et al., “A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases,” Cureus, Jan. 4, 2021, vol. 13, No. 1, Article No. e12482, 8 Pages, doi: 10.7759/…
[cited by applicant]
Trachtman H., et al., “A Phase 1, Single-Dose Study of Fresolimumab, an Anti-TGF-(beta) Antibody, in Treatment-Resistant Primary Focal Segmental Glomerulosclerosis,” Kidney International, Mar. 2, 2021, vol. 79, pp. 1236…
[cited by applicant]
Vajdos F.F., et al., “Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology, 2002, vol. 320, No. 2, pp. 415-428.
[cited by applicant]
Wasserman R.L., et al., “Primary Structure of the Variable Regions of Two Canine Immunoglobulin Heavy Chains”, Biochemistry, 1977, vol. 6, pp. 3160-3168.
[cited by applicant]
Wasserman R.L., et al., “The Amino Acid Sequence of the Light Chain Variable Region of a Canine Myeloma Immunoglobulin: Evidence That the VK Subgroups Predated Mammalian Speciation”, Immunochemistry, 1978, vol. 15, pp. …
[cited by applicant]
Yarilin A.A., “Fundamentals Immunology: Textbook. Moscow”, Medicine, 1999, 608 Pages, 5 Pages, See p. 171, Second Paragraph, pp. 171-173.
[cited by applicant]